Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 117

1.

[Why to treat a total chronic coronary occlusion?]

Marechal P, Gach O, Davin L, Martinez C, Lempereur M, Magnee M, Lancellotti P.

Rev Med Suisse. 2017 Aug 23;13(571):1406-1409. French.

PMID:
28837276
2.

Native metabotropic glutamate receptor 4 depresses synaptic transmission through an unusual Gαq transduction pathway.

Chardonnet S, Bessiron T, Ramos CI, Dammak R, Richard MA, Boursier C, Cadilhac C, Coquelle FM, Bossi S, Ango F, Le Maréchal P, Decottignies P, Berrier C, McLean H, Daniel H.

Neuropharmacology. 2017 Jul 15;121:247-260. doi: 10.1016/j.neuropharm.2017.04.036. Epub 2017 Apr 26.

PMID:
28456688
3.

High phosphatidylinositol 4-phosphate (PI4P)-dependent ATPase activity for the Drs2p-Cdc50p flippase after removal of its N- and C-terminal extensions.

Azouaoui H, Montigny C, Dieudonné T, Champeil P, Jacquot A, Vázquez-Ibar JL, Le Maréchal P, Ulstrup J, Ash MR, Lyons JA, Nissen P, Lenoir G.

J Biol Chem. 2017 May 12;292(19):7954-7970. doi: 10.1074/jbc.M116.751487. Epub 2017 Mar 16.

PMID:
28302728
4.

Esters of oligo-(glycerol carbonate-glycerol): New biobased oligomeric surfactants.

Holmiere S, Valentin R, Maréchal P, Mouloungui Z.

J Colloid Interface Sci. 2017 Feb 1;487:418-425. doi: 10.1016/j.jcis.2016.10.072. Epub 2016 Oct 26.

PMID:
27810510
5.

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.

Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; GARFIELD-AF Investigators.

Br J Haematol. 2016 Aug;174(4):610-23. doi: 10.1111/bjh.14084. Epub 2016 Apr 12.

PMID:
27071942
6.

Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.

Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators.

JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734.

PMID:
26547357
7.

Adhesion characterization and defect sizing of sandwich honeycomb composites.

Ndiaye EB, Maréchal P, Duflo H.

Ultrasonics. 2015 Sep;62:103-11. doi: 10.1016/j.ultras.2015.05.007. Epub 2015 Jun 18.

PMID:
26138595
8.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.

9.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.

N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

10.

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.

Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators.

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556. Epub 2015 Feb 24.

11.

S-palmitoylation and s-oleoylation of rabbit and pig sarcolipin.

Montigny C, Decottignies P, Le Maréchal P, Capy P, Bublitz M, Olesen C, Møller JV, Nissen P, le Maire M.

J Biol Chem. 2014 Dec 5;289(49):33850-61. doi: 10.1074/jbc.M114.590307. Epub 2014 Oct 9.

12.

Ultrasonic broadband characterization of a viscous liquid: methods and perturbation factors.

Ghodhbani N, Marechal P, Duflo H.

Ultrasonics. 2015 Feb;56:308-17. doi: 10.1016/j.ultras.2014.08.013. Epub 2014 Sep 6.

PMID:
25238692
13.

First proteomic study of S-glutathionylation in cyanobacteria.

Chardonnet S, Sakr S, Cassier-Chauvat C, Le Maréchal P, Chauvat F, Lemaire SD, Decottignies P.

J Proteome Res. 2015 Jan 2;14(1):59-71. doi: 10.1021/pr500625a. Epub 2014 Sep 19.

PMID:
25208982
14.

Ivabradine in stable coronary artery disease without clinical heart failure.

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators.

N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.

15.

Development of an efficient qRT-PCR assay for quality control and cellular quantification of respiratory samples.

Resa C, Magro S, Marechal P, Barranger C, Joannes M, Miszczak F, Vabret A.

J Clin Virol. 2014 Jul;60(3):270-5. doi: 10.1016/j.jcv.2014.03.019. Epub 2014 Apr 13.

PMID:
24809729
16.

Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M; ASTRONAUT Investigators and Coordinators.

Eur Heart J. 2013 Oct;34(40):3117-27. doi: 10.1093/eurheartj/eht342. Epub 2013 Sep 2.

17.

Comparative proteomic analysis of Streptomyces lividans Wild-Type and ppk mutant strains reveals the importance of storage lipids for antibiotic biosynthesis.

Le Maréchal P, Decottignies P, Marchand CH, Degrouard J, Jaillard D, Dulermo T, Froissard M, Smirnov A, Chapuis V, Virolle MJ.

Appl Environ Microbiol. 2013 Oct;79(19):5907-17. doi: 10.1128/AEM.02280-13. Epub 2013 Jul 19.

18.

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators.

JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.

PMID:
23478743
19.

Treatment of anemia with darbepoetin alfa in systolic heart failure.

Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ; RED-HF Committees; RED-HF Investigators.

N Engl J Med. 2013 Mar 28;368(13):1210-9. doi: 10.1056/NEJMoa1214865. Epub 2013 Mar 10.

20.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators.

Eur J Heart Fail. 2013 Mar;15(3):334-41. doi: 10.1093/eurjhf/hfs204. Epub 2013 Jan 17.

Supplemental Content

Loading ...
Support Center